51 results about "Malignant disease" patented technology

Biomarkers can be assessed for a variety of uses, including screening, detection, diagnosis, prognosis, risk prediction, disease progression, recurrence, selection of treatment, therapy response, to evaluate a subject's health status, whether the subject presents with no evidence of disease, or a benign or malignant condition such as cancer. Compositions (antibodies, polypeptide and polynucleotide markers) and methods are provided herein, which find application in the early detection of cancer, in the early detection of disease relapse and in monitoring therapy response.

This disclosure provides: (i) a method of using an anticeramide antibody or an antigen-binding fragment thereof to improve hematopoietic stem cell transplantation for the treatment of various non-malignant and malignant diseases; and (ii) a composition for such treatment.

The present application relates to the field of artificial intelligence and stomatology technology, and discloses a dynamic risk stratification monitoring system for potential malignant diseases in the oral cavity, which comprises a multi-modal data acquisition module, an intelligent risk assessment module, a risk grade division module and a dynamic monitoring module. The present application collects multi-modal data of the patient, including the patient's clinical behavior data, pathological data and basic identity information, carries out multi-dimensional analysis on the collected data to obtain behavior risk factors, pathological risk factors and basic risk factors, weights and sums the three factors to obtain a comprehensive risk coefficient, divides the current risk level of the patient based on the comprehensive risk coefficient, including low risk, medium risk and high risk, and draws a dynamic risk change curve of the patient based on the comprehensive risk coefficient, and determines whether to issue a warning according to the slope of the curve to attract the attention of medical staff to the current patient.

A device and a method, which is individual to a patient, treat malignant diseases by using selectively acting tumor-destructive mechanical pulses (TMI). The tumor-destructive pulse shapes and frequency are determined using physical cell properties, which are individual to each patient. The device is controlled in such that lethal pulse fields are applied in the tumor area.

Although compounds for treating or ameliorating malignant diseases have been proposed, patients had to endure a large burden since many of such compounds could not be orally ingested. Mangiferin has an effect of ameliorating malignant diseases through oral ingestion. However, such effect is minor and realistically it was not easy to ingest mangiferin. Further, in order to develop more effective pharmaceutical agents and the like for treating malignant diseases, it has been considered constantly necessary to obtain new or improved forms of an existing medical agent for inhibiting kinases such as NIK. A compound represented by formula (11) has an effect of ameliorating malignant diseases through oral ingestion, and can exhibit said effect with an amount less than that for mangiferin.

The present invention relates to T cell receptors (TCRs) that bind the HLA-A*02 restricted peptide GVYDGREHTV (SEQ ID NO: 1) derived from the germline cancer antigen MAGE A4. Said TCRs may comprise non-natural mutations within the alpha and / or beta variable domains relative to a native MAGE A4 TCR. The TCRs of the invention are particularly suitable for use as novel immunotherapeutic reagents for the treatment of malignant disease.

The present invention relates to binding molecules comprising a T-cell receptor (TCR) variable domain capable of binding to a PIWIL1 peptide-HLA complex. The present invention also relates to the use of such molecules for the treatment of malignant diseases.

The invention relates to pyrrolo[2,1-c][1,4]benzodiazepines (PBDs) compounds comprising a halogen or a tautomer thereof, or a salt thereof, or a salt of a tautomer thereof, and pharmaceutical compositions thereof which are useful as medicaments, as drug payloads in targeting moiety-drug conjugates and, in particular, in treating proliferative and / or malignant diseases. These PDBs are a compound of formula (I) or a tautomer thereof, or a salt thereof, or a salt of a tautomer thereof.

The application discloses a kind of cross-scale, multi-mode, visual biological detection device and detection method, belong to biological detection technical field, including: X-ray fluorescence imaging module, mechanical spectroscopy adhesion monitoring module, signal integration processing module.X-ray fluorescence imaging module is used for the acquisition, optimization, coding and identification of biological sample blue, green, red and near-infrared color pattern, mechanical spectroscopy adhesion monitoring module is used for real-time, dynamic monitoring and recording to biological sample active adhesion, through the collaborative processing analysis of X-ray optical signal and mechanical spectroscopy signal of the biological sample to be measured, realize the fluorescence visual of biological sample morphology, structure component and the accurate acquisition of biological activity data, for the research and application of cross-scale, multi-mode, visual contrast agent of mechanical spectroscopy and X-ray excited fluorescence imaging provides equipment support, promote its development optimization and conversion application in biomedical field such as inflammation infection, malignant disease, tumor diagnosis.

Provided herein, among other things, is a cell-based therapeutic for the treatment of a non-malignant disease of the lung. In some embodiments, the therapeutic may comprise a cell comprising a molecular circuit comprising: (i) a binding-triggered transcriptional switch (BTTS) that binds to RAGE (Receptor for Advanced Glycation Endproducts), (ii) a nucleic acid sequence encoding an immunosuppressive protein, a growth factor and / or an anti-fibrotic agent; and (iii) a regulatory sequence operably linked to (ii) that is responsive to the binding-triggered transcriptional switch, wherein binding of the binding-triggered transcriptional switch to RAGE activates expression of the immunosuppressive protein, growth factor and / or the anti-fibrotic agent in the lung. Alternatively or in addition, the therapeutic may be a T cell (Treg) comprising an engineered immune receptor that recognizes RAGE. Also provided is a method for decreasing inflammation in the lung and / or inducing repair of lung tissue.

The invention relates to tinostamustine for use in the treatment of lymphoma or a T-cell malignant disease. Tinostamustine may cause side effects when administered to a patient, and it is desirable to minimise such effects. The present invention defines an improved treatment, wherein the dose of tinostamustine administered is varied based on the patient's platelet count.

The invention discloses an oral potential malignant disease canceration time prediction system, electronic equipment and a medium, and the system comprises a data acquisition module, a data division module, a model construction module, a model training module and a time prediction module. And the risk prediction module is used for predicting the cancerization risk of the patient by using the artificial intelligence model with the best prediction accuracy, and determining the risk values of cancerization in the first time period and the second time period, or determining the time period with the higher cancerization possibility. According to the technical scheme, the canceration risk prediction probability values of the patient in multiple time periods are innovatively output by adopting the artificial intelligence model in combination with an oversampling technology and ending weight adjustment, a more comprehensive and specific prediction result can be provided for the patient, and personalized follow-up visit and formulation of a treatment scheme are facilitated.

The present invention relates to a binding molecule comprising a T cell receptor (TCR) variable domain and capable of binding a PRAME peptide-HLA complex. In particular, the present invention relates to a binding molecule capable of binding to PYLGQMINL (SEQ ID NO: 1) complexed with HLA-A24. The invention also relates to the use of these molecules in the treatment of malignant diseases.

The present invention relates to C-X-C motif chemokine ligand 10 (CXCL10) binding proteins and their use in methods of detecting and / or diagnosing a condition in a subject, including determining the level of CXCL10 in a subject. Specific antibodies that bind total CXCL10 (full length, N-terminally truncated and citrullinated) and antibodies that bind active CXCL10 (full length) are used to measure the level of total CXCL10 and active CXCL10 in ovarian cancer patient samples. The calculated ratio between active CXCL10 and total CXCL10 is lower in patients with malignant disease compared to patients with benign tumors or healthy individuals, and this calculated ratio is the basis for methods of diagnosing malignant disease, monitoring tumor burden and disease progression.

Disclosed herein are poly-inflammatory kinase (PINK) inhibitors, compositions containing PINK inhibitors. Methods for treating malignant diseases and autoimmune disorders using the PINK inhibitors are also disclosed.

The invention discloses a human breast benign and malignant disease body surface scanning detection method and device and a medium, and belongs to the technical field of biomedical instruments. The method comprises the following steps: acquiring depth data and an RGB image of a mammary gland area; planning a scanning path based on the depth data; controlling a mechanical arm to drive an optical fiber Raman probe to scan along the path; acquiring spectral data and preprocessing the spectral data; and synchronously marking the recognition result on the RGB image and displaying the RGB image. A mechanical scanning device is matched with an optical fiber Raman light probe, three-dimensional modeling of a mammary gland area is obtained through the assistance of an active infrared stereoscopic vision technology, a scanning path is automatically planned through an image edge detection algorithm, all-directional, full-automatic and high-sampling-density self-adaptive scanning is carried out on the human mammary gland, and the human mammary gland scanning precision is improved. And the benign and malignant substances of the breast tissue are judged by combining high-precision abnormal Raman spectrum detection and a mode recognition algorithm.

A method for expanding a population of gamma delta T-cells is provided, wherein isolated activated peripheral blood mononuclear cells (PBMCs) are cultured in a medium comprising transforming growth factor beta (TGF-beta) under conditions favoring the production of effector gamma delta T-cells having therapeutic activity against a malignant disease. The use of TGF-beta in the production of effector cells, in particular Vgamma9Vdelta2 T-cells, is also described and claimed.

An EP300 / CBP inhibitor, specifically provided is a compound as shown in formula I, or a deuterated product thereof, or a salt thereof, or a conformational isomer thereof, or a crystal form thereof, or a solvate thereof. The compound is highly selective for EP300 / CBP, and can effectively inhibit the activity of EP300 / CBP; in addition, the compound has an excellent inhibitory effect on various tumor cells including prostate cancer cells, leukemia cells, breast cancer cells and multiple myeloma cells. The compound has broad application prospects in the preparation of an EP300 / CBP inhibitor, and drugs for preventing and / or treating tumors, myeloid hematopoietic stem / progenitor cells malignant disease, and regulating regulatory T cells.

The invention relates to a method for preparing porphyrin compounds of formula (I) or metal derivatives, salts and solvates thereof, in particular tin (IV) phosphate derivatives thereof: wherein each of R1, R2, R3, R4, R5 and R6 is independently selected from H, methyl, ethyl, halogen, methoxy, ethoxy, NR 'R '', C1-2 haloalkyl, C1-2 alkylamine and C (O) CH3. The invention also relates to the use of such porphyrins as medicaments, in particular as medicaments for the treatment of proliferative and / or malignant diseases, such as cancer, and for the treatment or inhibition of metastasis, and to pharmaceutical compositions containing such porphyrins.

The present invention provides compounds of formula (I) or an enantiomer thereof, particularly the R-enantiomer, a diastereomer thereof, its hydrates, its solvates, its crystal forms, its tautomers or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, X and A are as defined herein. Said compounds of formula (I) are inhibitors of insulin-like growth factor 2 mRNA binding proteins (IGF2BP). Provided are novel inhibitors of IGF2BPs and processes for manufacturing the same. The invention further relates to a compound of formula (I) or a pharmaceutical composition for use in the treatment of any malignant disorder, including primary disease, metastases or recurrent neoplasia, which exhibits expression of IGF2BP1 in a manner amenable to the therapeutic intervention.

We disclose the generation and training of Generative Adversarial Networks (GAN) to synthesize clinical images with skin conditions. Synthetic images for a pre-specified skin condition are generated, while being able to vary its size, location and the underlying skin color. We demonstrate that the generated images are of high fidelity using objective GAN evaluation metrics. The synthetic images are not only visually similar to real images, but also embody the respective skin conditions. Additionally, synthetic skin images can be used as a data augmentation technique for training a skin condition classifier, and improve the ability of the classifier to detect rare but malignant conditions.

The application discloses a kind of accurate infrared thermal imaging inspection equipment, it is related to medical instrument technical field, including first thermal imaging tube, the front end of the first thermal imaging tube is provided with flexible first horn-shaped heat shield;Second thermal imaging tube, the second thermal imaging tube is movably sleeved in the first thermal imaging tube, and the front end of the second thermal imaging tube is provided with flexible second horn-shaped heat shield;Operating handle, the operating handle is fixed to the second thermal imaging tube end away from the second horn-shaped heat shield, first adjusting mechanism for controlling the first thermal imaging tube back and forth movement is arranged on the operating handle;Thermal imaging assembly, the thermal imaging assembly is arranged on the first thermal imaging tube side close to the first horn-shaped heat shield.This application can be independently controllable visual introduction natural cavity according to demand, and accurate imaging is realized in target range, to create new mode of clinical malignant disease diagnosis and treatment and early diagnosis and treatment.

Provided herein are methods of treatment, compositions, systems and kits using polymer particles as restraints of neutrophil function. Such methods include, but are not limited to, methods of preventing, treating, and / or ameliorating inflammatory diseases, infections, autoimmune diseases, malignant diseases, and other diseases or conditions in which neutrophils may be implicated. In some embodiments, polymer particles are useful for diagnosing neutrophil related diseases or conditions.

A method for diagnosing a malignant proliferative disease or disorder in a subject, and / or for following up, monitoring or prognosticating the therapy of a malignant proliferative disease or disorder in a subject is disclosed. The method is based on measurement of platelet-mediated fibrinogen-like protein 2 (FGL2) activity in a sample essentially comprising platelets obtained from the subject. In accordance with the disclosed method, platelet-mediated FGL2 activity level higher than control is indicative of the presence of a malignant proliferative disease or disorder in a subject.

Biomarkers can be assessed for a variety of uses, including screening, detection, diagnosis, prognosis, risk prediction, disease progression, recurrence, selection of treatment, therapy response, to evaluate a subject's health status, whether the subject presents with no evidence of disease, or a benign or malignant condition such as cancer. Compositions (antibodies, polypeptide and polynucleotide markers) and methods are provided herein, which find application in the early detection of cancer, in the early detection of disease relapse and in monitoring therapy response.

This application relates to the field of biotechnology, specifically disclosing a methylation molecular marker and its detection kit for early warning of oral mucosal cancer. The methylation molecular markers are the ZNF582 and SHOX2 genes. This application provides important molecular information for oral cancer screening by detecting the methylation levels of the ZNF582 and SHOX2 genes. The molecular markers of this application have high accuracy, sensitivity, and specificity, providing an important reference for early warning of oral mucosal cancer. Furthermore, the detection method is simple, rapid, low-cost, and convenient to sample, which can help achieve non-invasive early warning of potential oral malignant diseases, showing promising application prospects.

The present invention relates to binding molecules comprising a T cell receptor (TCR) variable domain capable of binding to a PRAME peptide-HLA complex. In particular, the present invention relates to binding molecules that bind to PYLGQMINL (SEQ ID NO: 1) complexed with HLA-A24. The present invention also relates to the use of such molecules for the treatment of malignant diseases.

The application discloses a lung nodule benign and malignant disease risk prediction system, an electronic device and application, takes TCR immune repertoire sequencing data of an individual peripheral blood ex vivo sample as the only input, forms an end-to-end prediction system from original TCR clone type data to lung nodule malignant risk probability output through sequencing data quality control, six-dimensional immune characterization, derived feature construction, RF-LASSO-RFE stable screening and two-level heterogeneous stacking probability fusion, wherein the six-dimensional immune characterization includes V / J gene use preference, clone amplification and length distribution, CDR3 core amino acid motif, sequence convergence, tumor specificity enrichment score and ecological diversity. The application can highlight the independent prediction value of the TCR molecular signal itself, improve the interpretability, robustness and generalization ability of small sample high-dimensional immune repertoire data, and can be used for non-invasive auxiliary evaluation, follow-up monitoring and lung cancer early screening of lung nodule benign and malignant diseases.

Various methods of treating a disease or condition, such as cancer, autoimmune disease, or any disease involving cellular proliferation are presented herein comprising administering to the subject an effective amount of an HPDL inhibitor compound or pharmaceutical composition as described herein.